Health Condition 1: null- All the patients presenting with bleeding esophageal varices due to cirrhosis presenting to the emergency department during the study period.
Conditions
Interventions
Intervention1: Octreotide: Octreotide, a somatostatin analogue is a vasoactive amine used in decreasing portal hypertension. In case of active upper gastrointestinal bleeding due to esophageal varices
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: All patients presenting with bleeding esophageal varices due to cirrhosis to the emergency department during the study period
Exclusion criteria
Exclusion criteria: (1) Non cirrhotic patients with portal hypertension. (2) Extremes of ages; 60 years. (3) Patients in hepatic encephalopathy grades 3 and 4. (4) Patients with source of bleeding in addition to or other than esophageal varices which includes gastritis, ulcers, ectasias, gastric varices, portal gastropathy. (5) Patients already on vasoactive drugs for current episode of bleeding. (6)Patients already received endoscopic ligation for the current episode elsewhere. (7) Patients requiring Sengstaken Blakemore Tube(SBT) insertion. (8)Any history of past surgeries for portal hypertension. (9)Patients associated with severe cardiopulmonary disease or malignancy. (10)Patients not willing to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Re-bleeding rates in both the Octreotide and the Placebo groups are compared.Timepoint: Re-bleeding rates are compared in both the groups at the end of three days. | — |
Secondary
| Measure | Time frame |
|---|---|
| not applicableTimepoint: not applicable | — |
Countries
India
Contacts
Public ContactRaj Kumar N
JIPMER
Outcome results
None listed